Skip to main content
SpringerLink
Log in

Treatment of moderate-to-severe and active Graves’ orbitopathy: a step forward from the OPTIC study

  • Comment
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Bartalena L, Tanda ML (2009) Clinical practice Graves’ ophthalmopathy. N Engl J Med 360:994–1001

    Article  CAS  PubMed  Google Scholar 

  2. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, Wiersinga WM, and the European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kahaly GJ (2019) Immunotherapies for thyroid eye disease. Curr Opin Endocrinol Diabetes Obes 26:250–255

    Article  CAS  PubMed  Google Scholar 

  4. Tanda ML, Piantanida E, Cusini C, Masiello E, Bartalena L (2019) Can combination of glucocorticoids with other immunosuppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 42:351–352

    Article  CAS  PubMed  Google Scholar 

  5. Smith TJ, Bartalena L (2019) Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy? Eur J Endocrinol 181:D27–D43

    Article  CAS  PubMed  Google Scholar 

  6. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:885–887

    Article  CAS  PubMed  Google Scholar 

  8. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341–352

    Article  CAS  PubMed  Google Scholar 

  9. Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, For the European Group on Graves’ Orbitopathy (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 97:4454–4463

    Article  CAS  PubMed  Google Scholar 

  10. Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, Profilo MA, Mazzi B, Albano E, Vitti P, Marcocci C, Brunetto M, Marinò M (2012) Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol 172:269–276

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varèse, Italy

    M. L. Tanda, D. Gallo, S. Ippolito, L. Bartalena & E. Piantanida

Authors
  1. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Ippolito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Piantanida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bartalena.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Ethical appoval

This article does not contain any study with human participants or animals performed by any of the authors

Informed consent

The article did not involve humans; therefore, no informed content was needed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanda, M.L., Gallo, D., Ippolito, S. et al. Treatment of moderate-to-severe and active Graves’ orbitopathy: a step forward from the OPTIC study. J Endocrinol Invest 43, 1523–1525 (2020). https://doi.org/10.1007/s40618-020-01223-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-020-01223-7

Keywords

Search

Navigation